Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ola Blennow, MD, PhD
With
Karolinska University Hospital
Danderyd Hospital
Centrallasarettet Västerås
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients 18 years of age or older who have given their written consent to participate in the study.
Hospitalized and treated with oxygen for a maximum of 48 hours.
Verified Covid-19: Positive sample for Sars-Cov2 RNA or a positive Sars-Cov2 antigen test from the upper respiratory tract
Receives oxygen treatment.
Negative pregnancy test (women of childbearing potential)
Willing to exercise contraception categorized as "very effective" according to the Clinical Trial Facilitation Group during ongoing study treatment + 7 days (Appendix 2). (female research participant of childbearing potential)
You may not be if
Pregnancy, breast-feeding or planned pregnancy.
Hypersensitivity to ciclesonide or to any of the excipients.
Concomitant medication with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir.
Treatment with\> 8 l oxygen / min or supply of \> 50% oxygen with nasal high-flow cannula
Ongoing palliative care or expected survival of less than 72 hours.
Expected admission to the intensive care unit within 48 hours.
Active or inactive pulmonary tuberculosis.
Severe Liver Failure (Child-Pugh C)
Diagnosed with pulmonary arterial hypertension (PAH) or fibrosis.
Mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study.
Participates in or has recently participated in a clinical trial in the last 30 days. Previous participation in this study.
Clareo Health | Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
